2019
DOI: 10.3892/mmr.2019.10150
|View full text |Cite
|
Sign up to set email alerts
|

MicroRNA‑144‑3p may participate in the pathogenesis of preeclampsia by targeting Cox‑2

Abstract: Preeclampsia remains a major cause of maternal mortality and morbidity worldwide. It is generally accepted that the development of the placenta, including spiral artery remodelling, normal trophoblast cells function and maternal-fetal inflammation-immune interactions, is critical for the pathogenesis of preeclampsia. Several investigations have demonstrated that microRNAs (miRNAs/miRs) in the placenta may be potential molecular markers for diagnosis of preeclampsia. In the current study, the aim was to investi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
15
1

Year Published

2020
2020
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 20 publications
(16 citation statements)
references
References 31 publications
0
15
1
Order By: Relevance
“…Preeclampsia (PE), featured by proteinuria and hypertension [ 1 ], is a major cause of fetal and maternal mortality and morbidity in human pregnancy [ 2 ]. The etiology and pathogenesis of PE are not clear [ 3 ], which has been reported to be associated with abnormal trophoblast invasion resulting in maternal endothelial dysfunction, chronic placental malperfusion and hypertension with adverse outcomes [ 4 ]. With the exception of fetal and placental delivery, there is no specific therapy for PE [ 5 ].…”
Section: Introductionmentioning
confidence: 99%
“…Preeclampsia (PE), featured by proteinuria and hypertension [ 1 ], is a major cause of fetal and maternal mortality and morbidity in human pregnancy [ 2 ]. The etiology and pathogenesis of PE are not clear [ 3 ], which has been reported to be associated with abnormal trophoblast invasion resulting in maternal endothelial dysfunction, chronic placental malperfusion and hypertension with adverse outcomes [ 4 ]. With the exception of fetal and placental delivery, there is no specific therapy for PE [ 5 ].…”
Section: Introductionmentioning
confidence: 99%
“…MiR‐144‐3p can also regulate the development and progression of ovarian cancer through suppressing Pre‐B cell leukemia homeobox 3 (PBX3) expression (Li et al, 2020). Moreover, miR‐144‐3p may be involved in the pathogenesis of pre‐eclampsia, as research has found that miR‐144‐3p expression is downregulated in placentas from women with pre‐eclampsia compared with paired normal placentas, and also that miR‐144‐3p is negatively correlated with cyloxygenase‐2 expression, which is known to be increased in the placenta of patients with pre‐eclampsia (Hu et al, 2019). In this study, our bioinformatics analysis revealed that miR‐144‐3p is capable of binding to IL‐1β, and we observed a negative correlation between levels of IL‐1β and miR‐144‐3p in human OA synovial tissue.…”
Section: Discussionmentioning
confidence: 99%
“…Hu et al reported that the expression of miRNA-144-3p was decreased in preeclamptic placentas and it was negatively correlated with placental expression of cyclooxygenase-2 (Cox-2), an enzyme of prostaglandin synthesis, that may play an important role in the development of PE. The association between miRNA-144-3p and Cox-2 was also confirmed in vitro [ 75 ]. Guo et al demonstrated that miRNA-133a-3p can relieve the oxidative stress-induced apoptosis in the trophoblast cells through the BACH1/Nrf2/HO-1 signaling pathway [ 76 ].…”
Section: Micrornasmentioning
confidence: 91%